World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

WFSBP Task Force on Treatment Guidelines for Schizophrenia

Research output: Contribution to journalArticle

217 Citations (Scopus)

Abstract

These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) (Bandelow et al. 2008a,b, World J Biol Psychiatry 9:242, see Table 1). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia.

Original languageEnglish
Pages (from-to)2-44
Number of pages43
JournalWorld Journal of Biological Psychiatry
Volume14
Issue number1
DOIs
Publication statusPublished - 1 Feb 2013

Fingerprint

Biological Psychiatry
Antipsychotic Agents
Schizophrenia
Guidelines
Therapeutics
Evidence-Based Practice
MEDLINE
Libraries
Psychiatry
Publications
Databases
Pharmacology
Physicians

Keywords

  • Antipsychotics
  • Evidence-based guidelines
  • Long-term treatment
  • Schizophrenia
  • Side effects

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

@article{6c291e76f0c8487e8319939c20445d8b,
title = "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects",
abstract = "These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) (Bandelow et al. 2008a,b, World J Biol Psychiatry 9:242, see Table 1). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia.",
keywords = "Antipsychotics, Evidence-based guidelines, Long-term treatment, Schizophrenia, Side effects",
author = "{WFSBP Task Force on Treatment Guidelines for Schizophrenia} and Alkomiet Hasan and Peter Falkai and Thomas Wobrock and Jeffrey Lieberman and Birte Glenthoj and Gattaz, {Wagner F.} and Florence Thibaut and M{\"o}ller, {Hans J{\"u}rgen} and Altamura, {A. Carlo} and Nancy Andreasen and Barnes, {Thomas R.E.} and Ceylan, {M. Emin} and Ollivier, {Jorge Ciprian} and Timothy Crow and Danaci, {Aysen Esen} and Anthony David and Michael Davidson and Bill Deakin and Helio Elkis and Lars Farde and Wolfgang Gaebel and Bernd Gallhofer and Jes Gerlach and Hirsch, {Steven Richard} and Hojaij, {Carlos Roberto} and Michael Hwang and Hwo, {Hai Gwo} and Jablensky, {Assen Verniaminov} and Marek Jarema and John Kane and Takuja Kojima and Veronica Larach and Jeffrey Lieberman and Patrick McGorry and Herbert Meltzer and M{\"o}ller, {Hans J{\"u}rgen} and S. Mosolov and Driss Moussaoui and Oli, {Jean Pierre} and Palha, {Antonio Pacheco} and Asli Sarand{\"o}l and Mitsumoto Sato and Heinrich Sauer and Nina Schooler and Bilgen Taneli and Knorring, {Lars von} and Daniel Weinberger and Shigeto Yamawaki",
year = "2013",
month = "2",
day = "1",
doi = "10.3109/15622975.2012.739708",
language = "English",
volume = "14",
pages = "2--44",
journal = "World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2

T2 - Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

AU - WFSBP Task Force on Treatment Guidelines for Schizophrenia

AU - Hasan, Alkomiet

AU - Falkai, Peter

AU - Wobrock, Thomas

AU - Lieberman, Jeffrey

AU - Glenthoj, Birte

AU - Gattaz, Wagner F.

AU - Thibaut, Florence

AU - Möller, Hans Jürgen

AU - Altamura, A. Carlo

AU - Andreasen, Nancy

AU - Barnes, Thomas R.E.

AU - Ceylan, M. Emin

AU - Ollivier, Jorge Ciprian

AU - Crow, Timothy

AU - Danaci, Aysen Esen

AU - David, Anthony

AU - Davidson, Michael

AU - Deakin, Bill

AU - Elkis, Helio

AU - Farde, Lars

AU - Gaebel, Wolfgang

AU - Gallhofer, Bernd

AU - Gerlach, Jes

AU - Hirsch, Steven Richard

AU - Hojaij, Carlos Roberto

AU - Hwang, Michael

AU - Hwo, Hai Gwo

AU - Jablensky, Assen Verniaminov

AU - Jarema, Marek

AU - Kane, John

AU - Kojima, Takuja

AU - Larach, Veronica

AU - Lieberman, Jeffrey

AU - McGorry, Patrick

AU - Meltzer, Herbert

AU - Möller, Hans Jürgen

AU - Mosolov, S.

AU - Moussaoui, Driss

AU - Oli, Jean Pierre

AU - Palha, Antonio Pacheco

AU - Sarandöl, Asli

AU - Sato, Mitsumoto

AU - Sauer, Heinrich

AU - Schooler, Nina

AU - Taneli, Bilgen

AU - Knorring, Lars von

AU - Weinberger, Daniel

AU - Yamawaki, Shigeto

PY - 2013/2/1

Y1 - 2013/2/1

N2 - These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) (Bandelow et al. 2008a,b, World J Biol Psychiatry 9:242, see Table 1). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia.

AB - These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) (Bandelow et al. 2008a,b, World J Biol Psychiatry 9:242, see Table 1). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia.

KW - Antipsychotics

KW - Evidence-based guidelines

KW - Long-term treatment

KW - Schizophrenia

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=84872356828&partnerID=8YFLogxK

U2 - 10.3109/15622975.2012.739708

DO - 10.3109/15622975.2012.739708

M3 - Article

C2 - 23216388

AN - SCOPUS:84872356828

VL - 14

SP - 2

EP - 44

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

SN - 1562-2975

IS - 1

ER -